TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01354301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximabe
Description: days 0 and 4, according to the package insert instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximabe
Description: days 0 and 4, according to the package insert instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate sodium
Description: 720 mg BID. This dose will be reduced according to adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
Study: NCT00920829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 Mg
Description: Naltrexone 25 or 50 mg per titration schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 Mg
Description: Naltrexone 25 or 50 mg per titration schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04022343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study: NCT04682873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enisamium Iodide
Description: Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.
Study: NCT01545843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep scheduling
Description: 8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
Study: NCT01354301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
Study: NCT03017911

Intervention type: PROCEDURE
Intervention: Piccline
Study: NCT03494842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS)
Description: The active TENS unit (delivers electrical stimulation) with indicator light

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcutaneous nerve stimulation (TENS)
Description: the placebo TENS unit (delivers no electrical stimulation) with indicator light
Study: NCT04619745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Home and Play-Based Physical Activity Plans
Description: Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
Study: NCT03327506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 0.5 mg
Description: alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
Study: NCT02391233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-WORTH
Description: E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
Study: NCT04576195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real PENS
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One single session
Study: NCT00557505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03732010
Description: IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
Study: NCT04099953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels
Description: Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels
Description: Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
Study: NCT00652574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
Study: NCT03442920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This group made exercise for 12 week/3 times a week.
Study: NCT01593878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TV
Description: test taken with TV on
Study: NCT02181959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaton® with DMAE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaton® without DMAE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02391233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streamlined HIV Testing
Description: In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Streamlined HIV Testing
Description: In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
Study: NCT02346825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy with cast
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy with splint
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation bimanual
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
Study: NCT00862511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation of a coated Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation of a Standard Total Knee Arthroplasty
Study: NCT02044198

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMP2.1/AS01B
Description: 50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Study: NCT02271594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Training on Best Insulin Injection Technique
Description: The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard education on injection technique
Description: Usual and customary education and training normally provided injecting patients at the center
Study: NCT01080547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery for Colorectal Cancer
Description: Laparoscopic surgery for colorectal cancer using STORZ laparoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery for Colorectal Cancer
Description: Laparoscopic surgery for colorectal cancer using STORZ laparoscope

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX Chemotherapy
Description: XELOX chemotherapy
Study: NCT02737462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG200745 PPA
Description: CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
Study: NCT02614196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02756858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Study: NCT01080547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX Chemotherapy
Description: XELOX chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox6 chemotherapy
Description: Conventional (mFolfox6) chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox6 chemotherapy
Description: Conventional (mFolfox6) chemotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track Perioperative Treatment
Description: Fast track treatment during perioperation period
Study: NCT01724203

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01697137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant Video and Provider Cueing
Description: Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
Study: NCT00311792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LapSimGyn training until expert proficiency level is reached
Description: Two consecutive simulations reaching predefined expert level

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional clinical education
Study: NCT03659487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen
Description: Laparoscopic total (Nissen) fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupét
Description: Laparoscopic posterior 270 degrees partial fundoplication
Study: NCT03929302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
Study: NCT03828435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
Study: NCT03929302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
Study: NCT01978964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10
Description: ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
Study: NCT01452035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: single session of exercise
Study: NCT01080547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track Perioperative Treatment
Description: Fast track treatment during perioperation period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Perioperative Treatment
Description: Conventional treatment during perioperation period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Perioperative Treatment
Description: Conventional treatment during perioperation period
Study: NCT00412867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 0.6 mg/kg of Alteplase is intravenously administered
Study: NCT01842243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical pacing
Description: Pacemaker set to pace at right ventricular apex initially.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical pacing
Description: Pacemaker set to pace at right ventricular apex initially.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal pacing
Description: Pacemaker set to pace at right ventricular septum initially.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal pacing
Description: Pacemaker set to pace at right ventricular septum initially.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: MR conditional Pacemaker implanted in all study patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: MR conditional Pacemaker implanted in all study patients
Study: NCT01960361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE dental implant
Description: ICE- Implant Classical Esthetic implant